Printer Friendly

DEPRENYL U.S.A. ANNOUNCES NEW RESEARCH AGREEMENT AND PATENT APPLICATIONS IN THE FIELD OF WOMEN'S HEALTH CARE

 DEPRENYL U.S.A. ANNOUNCES NEW RESEARCH AGREEMENT
 AND PATENT APPLICATIONS IN THE FIELD OF WOMEN'S HEALTH CARE
 TORONTO, April 23 /PRNewswire/ -- Deprenyl U.S.A., Inc. (NASDAQ: DUSA) today announced the signing of a new research agreement between the company and Queen's University, at Kingston, Ontario, which focuses on development of 5-Aminolevulinic Acid Photodynamic Therapy (ALA PDT) as a non-surgical alternative to hysterectomy for women with excessive uterine bleeding.
 Initial pre-clinical work at Queen's demonstrates that ALA PDT (via the build-up of Protoporphyrin IX, a potent photosensitizer) can induce endometrial ablation (removal of the blood-producing lining of the uterus), without causing any significant damage to the myometrium (the muscle layers of the uterus), and without any apparent toxicity at therapeutic treatment levels.
 In recent testing, the investigators have also demonstrated the ALA induced build-up of Photoporphyrin IX in the endometrium of human uterine tissue specimens, without a significant build-up in the myometrium. Based upon these preliminary findings, the company believes this technique should be studied for human use, initially as a non- surgical alternative to hysterectomy for women with menorrhagia (excessive and painful uterine bleeding). This technique could also potentially be useful in the treatment of endometriosis and other gynecological conditions.
 Because of the important implications of this work, the company has decided to provide initial funding of approximately Cdn.$200,000 for the purpose of determining whether the technique is safe and efficacious, so that human clinical trial can be commenced.
 In addition, PARTEQ, the technology transfer arm of Queen's University, has recently submitted additional patent applications on behalf of Queen's, to the U.S. patent office. These claims add to the coverage in these and other areas of ALA PDT research. These patents, if they should issue, are subject to the company's existing license agreement with PARTEQ.
 Deprenyl U.S.A., Inc. (DUSA) is a development stage company established to develop prescription pharmaceutical products for all markets, including the United States and Canada, primarily in the field of photodynamic therapy, which combines the use of a pharmaceutical product such as ALA, with exposure to light to induce a therapeutic effect. DUSA is developing ALA PDT initially for the treatment of certain skin conditions, including basal cell carinomas, pre-cancerous actinic keratoses, and psoriasis. As reported in the March 9, 1992 letter to shareholders, the dermatological development program is proceeding on schedule, and remains the prime focus of the company.
 Deprenyl Research Limited owns 21.4 percent of DUSA and holds an option on an addition 2 million shares U.S.$9.00 per share.
 -0- 4/23/92
 /CONTACT: D. Geoffrey Shulman, president and CEO, or Edward L. Foster, CFO, 416-537-1070 or 416-537-4372, Joseph P. Castelli, vice president, 201-299-9070 (New Jersey), all of Deprenyl U.S.A.; or Irving L. Strauss of Strauss Corporate Communications, 212-768-2477, for Deprenyl/
 (DUSA) CO: Deprenyl USA Inc. ST: Ontario IN: MTC SU:


SM-AH -- NY048 -- 1807 04/23/92 11:11 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 23, 1992
Words:489
Previous Article:GAMMA INTERNATIONAL REPORTS FIRST QUARTER RESULTS; COMPANY IS NOW IN COMPLIANCE WITH NASD CAPITAL AND SURPLUS REQUIREMENTS
Next Article:SPRINT TO PROVIDE UNILEVER WITH GLOBAL MESSAGING SERVICE


Related Articles
DEPRENYL ADJOURNS APPLICATION FOR INJUNCTION
DEPRENYL RESEARCH REPORTS RECORD EARNINGS, STRONG SALES AND TENTH CONSECUTIVE INCREASED QUARTERLY DIVIDEND
DEPRENYL RESEARCH ELECTS MARTIN BARKIN PRESIDENT, CHIEF OPERATING OFFICER AND DIRECTOR
DEPRENYL ANIMAL HEALTH SIGNS WORLDWIDE EXCLUSIVE LICENSE WITH INNOVATIONS FOUNDATION
DEPRENYL ANIMAL HEALTH GRANTED PATENT FOR L-DEPRENYL (ANIPRYL) AS TREATMENT OF COGNITIVE DYSFUNCTION IN DOGS
DEPRENYL USA REPORTS RESULTS FOR SECOND QUARTER AND SIX MONTHS ENDING JUNE 30, 1992
DEPRENYL USA ANNOUNCES NO CHANGE AT COMPANY TO ACCOUNT FOR SHARE PRICE PRESSURE
DEPRENYL ANIMAL HEALTH, INC. REPORTS U.S. PATENT ALLOWANCE FOR USE OF ANIPRYL IN TREATMENT OF CANINE CUSHING'S DISEASE
DEPRENYL USA, INC. SIGNS AGREEMENT ON ADDITIONAL PHOTODYNAMIC CANCER FIGHTING COMPOUNDS
DEPRENYL USA, INC. RECEIVES NEW PATENTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters